Aptevo Therapeutics(APVO)
$0.66-0.10 (-13.16%)
APVO
Aptevo Therapeutics stock drug pipeline
$0.66
At close:-0.10 (-13.16%)
Want to see APVO full AI Analyst Report?
Aptevo Therapeutics (APVO) Drug Pipeline
751 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Azacitidine, Venetoclax, Apvo436 | Acute Myeloid Leukemia (Aml) | Phase I | Recruiting | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | Oct 04, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Azacitidine, Venetoclax, Apvo436 | Phase I | Acute Myeloid Leukemia (Aml) | Recruiting | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | Oct 04, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Aptevo (APVO) have in its pipeline
Aptevo Therapeutics APVO is currently developing the following drugs: Azacitidine, Venetoclax, Apvo436. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
